金融界9月19日消息，复锐医疗科技在2024年中期报告中，未经审核的业绩显示，公司收益由171.6百万美元降至168.7百万美元，同比下降1.7%。收益下降主要因北美经济环境充满挑战。然而这部分下降被亚太区、欧洲及中东及非洲地区的双位数收益增长抵消。报告期内，公司绝大部分的收益来自医疗美容产品线，占总收益的88.5%，同比增加1.3%至149.3百万美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.